Literature DB >> 21735357

[Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies].

M Pavel1.   

Abstract

The clinical presentation of neuroendocrine neoplasms (NEN) varies depending on the site of origin, functional activity, histological differentiation and tumor growth behavior. Therapeutic strategies aim to improve the symptoms of clinical syndromes related to the secretion of amines and peptides, inhibit tumor growth and prevent complications. Novel molecular targeted drug therapies offer new treatment options in addition to established therapies, such as somatostatin analogs and chemotherapy. The precise positioning of these drugs and of peptide receptor radionuclide therapy still needs to be defined. In general, the different medical treatments are used in a sequential way and are in part combined with surgical and loco-regional/ablative procedures in a highly individualized approach. In certain clinical conditions, however, established treatment strategies are followed. This review presents the management of patients with small intestinal and pancreatic NEN with respect to the functionality and tumor grading. The use of novel targeted drug therapy is included in a therapeutic algorithm.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735357     DOI: 10.1007/s00104-011-2073-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  24 in total

1.  ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.

Authors:  Beata Kos-Kudła; Dermot O'Toole; Massimo Falconi; David Gross; Günther Klöppel; Anders Sundin; John Ramage; Kjell Oberg; Bertram Wiedenmann; Paul Komminoth; Eric Van Custem; Mohandes Mallath; Mauro Papotti; Martyn Caplin
Journal:  Neuroendocrinology       Date:  2010-05-19       Impact factor: 4.914

2.  Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma.

Authors:  Barbro Eriksson; Günter Klöppel; Eric Krenning; Hakan Ahlman; Ursula Plöckinger; Bertram Wiedenmann; Rudolf Arnold; Christoph Auernhammer; Meike Körner; Guido Rindi; Stefan Wildi
Journal:  Neuroendocrinology       Date:  2007-12-12       Impact factor: 4.914

3.  Glycemic control in patients with insulinoma treated with everolimus.

Authors:  Matthew H Kulke; Emily K Bergsland; James C Yao
Journal:  N Engl J Med       Date:  2009-01-08       Impact factor: 91.245

4.  Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

Authors:  Homayoun Shojamanesh; Fathia Gibril; Adeline Louie; Jeremiah V Ojeaburu; Showkat Bashir; Alaa Abou-Saif; Robert T Jensen
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.

Authors:  Ursula Ploeckinger; Guenter Kloeppel; Bertram Wiedenmann; Ruediger Lohmann
Journal:  Neuroendocrinology       Date:  2009-09-23       Impact factor: 4.914

7.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Authors:  Siegbert Faiss; Ulrich-Frank Pape; Michael Böhmig; Yvonne Dörffel; Ulrich Mansmann; Werner Golder; Ernst Otto Riecken; Bertram Wiedenmann
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors.

Authors:  Marie-Louise H Fjallskog; Eva T Janson; Ursula G Falkmer; Morten H Vatn; Kjell E Oberg; Barbro K Eriksson
Journal:  Neuroendocrinology       Date:  2008-02-18       Impact factor: 4.914

9.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

10.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.